List of adverse effects of nilotinib

This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence.[1][2][3][4][5][6]

## Contents

* 1 Very common
* 2 Common
* 3 Uncommon
* 4 References

## Very common[edit | edit source]

Very common (>10% incidence) adverse effects include:

* Headache
* Nausea
* Hypophosphataemia
* Hyperbilirubinaemia
* Alanine aminotransferase (ALT) increased
* Aspartate aminotransferase increased
* Lipase increased
* Rash
* Itchiness
* Hair loss
* Dry skin
* Muscle aches
* Fatigue

## Common[edit | edit source]

Common (1–10% incidence) adverse effects include:

* Constipation
* Diarrhoea
* Vomiting
* Upper abdominal pain
* Indigestion
* Joint pain
* Muscle spasms
* Pain in extremities
* Asthenia
* Peripheral oedema
* Folliculitis
* Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
* Skin papilloma
* Eosinophilia
* Lymphopenia
* Insomnia
* Anxiety
* Depression
* Diabetes mellitus
* Hypercholesterolaemia
* Hyperlipidaemia
* Hypertriglyceridaemia
* Hyperglycaemia
* Loss of appetite
* Dizziness
* Hypoaesthesia
* Peripheral neuropathy
* Eye pruritus
* Conjunctivitis
* Dry eye (including xerophthalmia)
* Vertigo
* Flushing
* Hypertension
* Angina pectoris
* Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
* QT interval prolonged
* Palpitations
* Cough
* Dyspnoea
* Abdominal distension
* Abdominal discomfort
* Taste changes
* Flatulence
* Abnormal liver function
* Bone pain
* Back pain
* Erythema
* Hyperhidrosis
* Contusion
* Acne
* Dermatitis (including allergic, exfoliative and acneiform)
* Night sweats
* Fever without an infectious cause
* Chest pain (including non-cardiac chest pain)
* Chest discomfort
* Decreased haemoglobin
* Increased blood amylase
* Increased blood alkaline phosphatase
* Gamma-glutamyltransferase increased
* Weight increased
* Increased blood insulin
* Increased lipoprotein (including very low density and high density)

## Uncommon[edit | edit source]

Uncommon (0.1–1% incidence) adverse effects include:

* Arteriosclerosis
* Bone marrow suppression
* Both increases and decreases of potassium levels
* Body temperature change sensation (both hot and cold)
* Chills
* Cognitive deficits[7]
* Conjunctival bleeding and redness
* Cyanosis
* Dental sensitivity to pain
* Bleeding into the lungs[8]
* Increased blood cholesterol and lipid levels
* Dystonia[7]
* Erectile dysfunction
* Eyelid swelling
* Flank pain
* Gastritis
* Gout
* Decreased calcium levels
* Jaundice
* Malaise
* Migraine
* Muscle pain and weakness
* Pancreatitis
* Paraesthesia
* Peripheral arterial occlusive disease
* Photopsia
* Pleural effusion
* Skin eruptions
* Skin pain
* Decreased globulins

## References[edit | edit source]

1. ↑ "Complete Nilotinib information from Drugs.com". Drugs.com. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
2. ↑ "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Archived (PDF) from the original on 4 February 2014. Retrieved 25 January 2014.
3. ↑ "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
4. ↑ "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Archived from the original on 6 April 2017. Retrieved 25 January 2014.
5. ↑ "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 17 July 2021. Retrieved 25 January 2014.
6. ↑ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
7. ↑ 7.0 7.1 Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019: 3679319. doi:10.1155/2019/3679319. PMC 6875312. PMID 31781436.
8. ↑ Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220. S2CID 43118790.`{{cite journal}}`: CS1 maint: multiple names: authors list (link)